Wright Lassiter III
Known title: DirectorCIK: 0001805909
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Quest Diagnostics Preps for Q3 Earnings Amid Dividend Focus. Quest Diagnostics is approaching its third-quarter earnings report, with recent coverage highlighting its position as a dividend-paying stock. The company maintains a 2.10% dividend yield and trades at a 24.7 P/E ratio. Analysts currently set an average price target of $251.40, which sits above the current trading range.
Transaction History
| FTV | ▼ Sell | Other | 5 | $300 | 9/25/2026 | View on chart |
| DGX | ▼ Sell | Other | 6 | $1K | 7/22/2026 | View on chart |
| FTV | ▼ Sell | Other | 4 | $257 | 7/2/2026 | View on chart |
| FTV | ▲ Buy | Grant | 3,350 | $0 | 6/9/2026 | View on chart |
| FTV | ▲ Buy | Grant | 1,925 | $115K | 6/9/2026 | View on chart |
| DGX | ▲ Buy | Grant | 1,142 | $0 | 5/20/2026 | View on chart |
| DGX | ▼ Sell | Other | 6 | $1K | 4/20/2026 | View on chart |
| FTV | ▼ Sell | Other | 5 | $257 | 3/26/2026 | View on chart |
| DGX | ▼ Sell | Other | 7 | $1K | 1/28/2026 | View on chart |
| FTV | ▼ Sell | Other | 5 | $257 | 12/26/2025 | View on chart |
| DGX | ▼ Sell | Other | 7 | $1K | 7/21/2025 | View on chart |
| FTV | ▲ Buy | Grant | 1,625 | $115K | 6/2/2025 | View on chart |
| FTV | ▲ Buy | Grant | 2,120 | $0 | 6/2/2025 | View on chart |
| DGX | ▲ Buy | Grant | 1,203 | $0 | 5/15/2025 | View on chart |
| FTV | ▲ Buy | Grant | 2 | $183 | 3/27/2025 | View on chart |
| FTV | ▲ Buy | Grant | 2 | $183 | 12/26/2024 | View on chart |
| FTV | ▲ Buy | Grant | 1,970 | $0 | 6/3/2024 | View on chart |
| FTV | ▲ Buy | Grant | 1,515 | $115K | 6/3/2024 | View on chart |
| DGX | ▲ Buy | Grant | 1,482 | $0 | 5/16/2024 | View on chart |
| FTV | ▲ Buy | Grant | 1,755 | $115K | 6/6/2023 | View on chart |
| FTV | ▲ Buy | Grant | 2,290 | $0 | 6/6/2023 | View on chart |
| DGX | ▲ Buy | Grant | 1,369 | $0 | 5/17/2023 | View on chart |
| FTV | ▲ Buy | Grant | 1,510 | $0 | 6/6/2022 | View on chart |
| FTV | ▲ Buy | Grant | 1,930 | $115K | 6/6/2022 | View on chart |
| DGX | ▲ Buy | Grant | 1,292 | $0 | 5/18/2022 | View on chart |
| FTV | ▲ Buy | Grant | 615 | $0 | 1/24/2022 | View on chart |
| FTV | ▲ Buy | Grant | 785 | $58K | 1/24/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
RBC lowers Fortive price target to $59
RBC Capital cut its price target for Fortive to $59 while maintaining a Sector Perform rating. Recent analysis suggests that while current demand remains stable, earnings growth in the second half of the year is not accelerating. This cautious outlook aligns with the stock trading near its recent support levels, reflecting a market that is waiting for clearer signs of momentum.
RBC lowers Fortive price target to $59. RBC Capital cut its price target for Fortive to $59 while maintaining a Sector Perform rating. Recent analysis suggests that while current demand remains stable, earnings growth in the second half of the year is not accelerating. This cautious outlook aligns with the stock trading near its recent support levels, reflecting a market that is waiting for clearer signs of momentum.